OS THERAPIES INCORPORATED (OSTX) Current Ratio
- Current ratio · latest quarter: Value 0.18×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.18× | Current assets / current liabilities. $3.64M ÷ $20.64M ≈ 0.18× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 3.64M USD | Assets, Current |
| Current obligations | 20.64M USD | Liabilities, Current |
| Cash and equivalents | (m) | |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.64M | $20.64M | (m) | (m) | (m) | (m) | (m) | (m) | 0.18× |
| 2026-03-31 | $917.55K | $16.95M | (m) | (m) | (m) | (m) | (m) | (m) | 0.05× |
| 2025-12-31 | $332.91K | $11.76M | (m) | (m) | (m) | (m) | (m) | (m) | 0.03× |
| 2025-09-30 | $2.32M | $4.15M | (m) | (m) | (m) | (m) | $3.37M | (m) | 0.56× |
| 2025-06-30 | $3.55M | $3.46M | (m) | (m) | (m) | (m) | $2.70M | (m) | 1.03× |
| 2025-03-31 | $4.10M | $3.54M | (m) | (m) | (m) | (m) | $1.62M | (m) | 1.16× |
| 2024-12-31 | $5.53M | $4.63M | (m) | (m) | (m) | (m) | $1.66M | (m) | 1.20× |
| 2024-09-30 | $1.97M | $2.58M | (m) | (m) | (m) | (m) | $1.77M | (m) | 0.76× |
| 2024-06-30 | $1.34M | $28.31M | (m) | (m) | (m) | (m) | $2.92M | (m) | 0.05× |
| 2024-03-31 | $1.04M | $26.46M | (m) | (m) | (m) | (m) | $2.80M | (m) | 0.04× |
| 2023-12-31 | $790.03K | $24.71M | (m) | (m) | (m) | (m) | $2.72M | (m) | 0.03× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |